QualityStocks
  The QualityStocks Daily Newsletter for Tuesday February 2nd, 2010 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters

1.

Stock Palooza (KING)

2.

OTC Picks (EVFN)

3.

White Hot Stocks (SPOM)


The QualityStocks Daily

Shrink Nanotechnologies, Inc. (INKN)

Today we are highlighting Shrink Nanotechnologies, Inc. (INKN) as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Shrink Nanotechnologies, Inc. is a nanotechnology company developing products and licensing opportunities in the solar energy production, biotechnology research, and development tools and medical diagnostics businesses. The Company bases their products on proprietary material, a pre-stressed plastic called NanoShrink™, and on their patent-pending manufacturing process called the ShrinkChip Manufacturing Solution™. Shrink Nanotechnologies, Inc. trades on the OTC Bulletin Board and they have their corporate headquarters in Carlsbad, California.

NanoShrink™ is the plastic substrate material the Company uses to build all of the products they design, prototype, and manufacture. Their primary NanoShrink™ substrate is made from a pre-stressed polystyrene material. By taking advantage of certain critical inherent characteristics, shrinkable polystyrene allows for the ultra-rapid direct patterning of complex, even three-dimensional, stacked polystyrene micro and nanostructures.

The Company's patent-pending process involves printing designed and related microstructures on a larger scale on NanoShrink and then uniformly shrinking them down to a nano-scale size. By using their technologies to "print" on a larger scale, and then "shrink" the same features down to the nano-scale, they eliminate the need for clean rooms and other highly complex robotics or tools needed to accomplish this.

Shrink Nanotechnologies, Inc. is a FIGA™ business - bringing together leaders from the worlds of Finance, Industry, Government and Academia to form a for-profit business. The result is Shrink Nanotechnologies and their technology being well received in leading academic journals. These include Nature Medicine™, Lab-on-a-Chip™ and Advanced Materials™. Most recently, MIT's Technology Review awarded their prestigious TR35 award to the Company's scientific founder, Dr. Michelle Khine.

Dr. Khine developed innovations that have become the core of what is now Shrink Nanotechnologies. The Company has 11 exclusive patent pending technologies and is developing products and licensing partnerships in three main vertical markets. These include Solar Energy, Medical and Diagnostic Sensors, and Research Tools to advance innovation in some of the most important medical fields.

Yesterday, Shrink Nanotechnologies, Inc. outlined key milestones for 2010, which they expect to have a significant impact on the solar, biotechnology, and medical diagnostics industries. The Company is rapidly progressing this year toward the commercialization of products and signing agreements with leading manufacturing and distribution multi-nationals.

Products on their way to market include The OptiSol Solar Concentrator. This is a first-of-its-kind nanotechnology-based plastic solar concentrator and film. In the biotechnology space, the StemDisc and CellAlign family of products are an important biotechnology and stem cell research tool for scientists. The Company's MetalFluor is a technology for the medical diagnostics field designed to increase inexpensively the sensitivity of fluorescence-based diagnostic tests. Shrink is in discussions to integrate their MetalFluor technology with existing leading diagnostic sensor platforms, replacing quartz, silicon, and other glass substrates used in products that measure fluorescent signals.

We're tracking Shrink Nanotechnologies, Inc. (INKN) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Shrink Nanotechnologies, Inc. (INKN) closed Tuesday's session at $1.25 on no volume.

Oilsands Quest, Inc. (BQI)

Yesterday, the Street reported on Oilsands Quest, Inc. (BQI), Tiny Gems, Stock Fortune Teller, Momentum Trades, StockEgg.com, Penny Invest, WallStreet.net, Daily Profit did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Oilsands Quest Inc. is exploring one of Canada's largest holdings of contiguous oil sands permits and licenses, located in Saskatchewan and Alberta. They are developing Saskatchewan's first global-scale oil sands discovery. They are leading the establishment of the province of Saskatchewan's emerging oil sands industry. Oilsands Quest, Inc. trades on the NYSE: Amex. They have their corporate headquarters in Calgary, Alberta.

Incorporated in Colorado, U.S.A., Oilsands Quest, Inc. engages in a variety of projects in the oil and gas industry in Western Canada with an emphasis on the oil sands. The Company's main operating subsidiaries are Oilsands Quest Sask Inc., Township Petroleum Corporation, and Oilsands Quest Technology Inc. The Company wholly owns and operates their resource rights. Since the fall of 2004 and the acquisition of their first oil sands exploration permits in northwest Saskatchewan, they have achieved many milestones. This includes declaring two discoveries – Axe Lake, Saskatchewan, and Raven Ridge, Alberta – and identifying a third area of interest, Wallace Creek, on the Alberta side of the contiguous lands.

On January 19, 2010, Oilsands Quest Inc. reported that they reached an agreement to sell their oil shale assets located near Pasquia Hills in Saskatchewan. This is to Canshale Corp.  Oilsands Quest has been examining alternative structures to develop their oil shale assets and provide a separate vehicle for funding and operating these assets. The Company determined that the best use of their financial and management resources continues to be in developing their significant portfolio of oil sands projects and exploration lands.

They will sell the oil shale properties to Canshale for consideration of CDN $1 million in cash and 8,000,000 shares of Canshale. The transaction is conditional on Canshale raising a minimum of CDN $12.5 million. Following the initial Canshale financing Oilsands Quest Inc. will retain an ownership interest of between 10 and 16 per cent in Canshale.

Today, Oilsands Quest Inc. announced their participation at the Insight Canadian Oil Sands Summit on Tuesday February 2, 2010. T. Murray Wilson, Chairman, President and Chief Executive Officer will be presenting a Corporate Update on the Company's current activities and plans.

Today, Oilsands Quest, Inc. (BQI) closed trading at $0.82 down 4.65 percent. Volume was 3,806,697.

Silicon Laboratories, Inc. (SLAB)

Trading Markets, The Best Newsletters, and Zacks.com reported earlier on Silicon Laboratories, Inc. (SLAB), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Trading on the NASDAQ, Silicon Laboratories, Inc. is a leader in high-performance, analog-intensive, mixed-signal ICs. Mixed-signal ICs enable the analog world to interact with the digital world of computing in products like set-top boxes, televisions, and cell phones. The Company's diverse portfolio of highly integrated, easy-to-use products offers their customers major advantages in performance, size, and power consumption. The Company is a global enterprise with operations, sales, and design activities worldwide. They have their headquarters in Austin, Texas.

Silicon Laboratories, Inc.'s portfolio of application specific and general-purpose products includes high-performance, mixed-signal 8-bit microcontrollers, broadcast audio and video solutions, ISOmodem® embedded modems, and ProSLIC® subscriber line interface-circuits. They also include silicon direct access arrangements (DAAs), clocks, and oscillators. These patented solutions serve a broad set of markets and applications including consumer, communications, computing, industrial, and automotive. 

Silicon Laboratories introduced the Si345x family in November 2009. These are the industry's most integrated, energy-efficient quad Power over Ethernet (PoE) Power Sourcing Equipment (PSE) controllers. The Si345x controllers are able to support four independent PoE (IEEE 802.3af) and PoE+ (IEEE 802.3at) PSE ports. The Si345x controllers offer real-time power measurement capabilities, energy-efficient powered device (PD) detection and disconnect algorithms, and the industry's lowest on-resistance power field-effect transistors (FETs) and sense resistors.

These features enable smaller, highly energy-efficient and lower-cost PoE/PoE+ Ethernet switches and midspans. The Company designed these to power multi-radio wireless access points, industrial automation systems, VoIP phones, and building security and surveillance systems.

Silicon Laboratories Inc. announced in November that Mitsumi selected their highly integrated Si2170 TV tuner for iDTV and set-top box modules. Mitsumi chose Silicon Laboratories' single-chip analog and digital TV tuner because of its leading performance, lowest system cost and strong roadmap for further integration. The Si2170 device enables Mitsumi to deliver significant size reduction and higher performance than using a traditional mixed oscillator phase-locked loop (MOPLL)-based solution.

In December 2009, Silicon Laboratories Inc. introduced a next-generation ac current sensor family that replaces traditional current transformers. This expands the Company's ISOpro isolation product portfolio. Their new Si85xx ac current sensors provide up to 5 kVrms of electrical isolation to ensure safety compliance for a variety of critical power delivery systems. These include ac-dc switching power supplies, isolated dc-dc supplies, motor control applications, and electronic lighting ballasts.

Yesterday, Silicon Laboratories Inc. reported that they would display their latest embedded mixed-signal and broadcast technologies at the International IC-China Conference & Exhibition (IIC-China, Booth 2C11) in Shenzhen, March 4-5, 2010. This is to help drive the next breakthroughs in smart home, smart metering, human interface, and AM/FM radio designs.

Silicon Laboratories, Inc. (SLAB) closed Tuesday's trading session at $44.35 up 1.07 percent. Volume was 1,211,817.

Starpharma Holdings Limited (SPHRY)

PennyStockDD.com reported today on Starpharma Holdings Limited (SPHRY), and we are highlighting the Company as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Starpharma Holdings Limited is a world leader in the development of dendrimer technology for pharmaceutical, life science, and other applications. Products based on SPL dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through license arrangements with partners including Siemens and Merck KgA. Starpharma Holdings has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc. in the United States. Starpharma Holdings Limited trades on the Pink Sheets.

In the pharmaceutical field, Starpharma is developing VivaGel® (SPL7013Gel) as a vaginal microbicide. Its design is to prevent the transmission of STIs, including HIV and genital herpes. Starpharma already has a significant licensing deal with SSL (owners of Durex® brand) for use of VivaGel® as a condom coating. Starpharma also has NIH funded development programs for VivaGel® for the prevention of viral sexually transmitted infections.

In addition, they have programs focused on drug delivery partnered with Elanco (Eli Lilly) and Stiefel (GSK), and a program for modifying pesticides with a multi-billion dollar U.S. agrochemical company. In May 2009, Starpharma and Elanco (Eli Lilly and Company's animal health division) signed an agreement to work together to develop new animal health products with enhanced properties.

The Company has specific programs in the areas of Drug Delivery and Drug Optimization technologies (using dendrimers to control where and when drugs go when introduced to the body) and Diagnostics. In addition, the Company is exploring dendrimer opportunities in materials science applications including water remediation.

Starpharma is assessing in-house leads in fields such as cancer, ophthalmology, arthritis, and targeted diagnostics. Their DNT, Inc. subsidiary provides additional avenues of commercialization in drug delivery, transfection reagents, and contrast agents for medical imaging such as MRI.  DNT is exploiting opportunities for industrial applications of dendrimers as specialty chemicals. Dendrimers may have applications in the electronics, oil, and plastics industries.

Yesterday, Starpharma Holdings Limited announced the signing of a new agreement with Eli Lilly and Company. With this agreement Starpharma's dendrimer drug delivery technology will undergo application to enhance compounds in Lilly's human pharmaceutical portfolio. Eli Lilly and Company will fund a collaborative research and development program. The aim is to create improved drugs incorporating Starpharma's proprietary delivery technology, to undergo commercialization by Eli Lilly and Company.

We have Starpharma Holdings Limited (SPHRY) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Starpharma Holdings Limited (SPHRY) closed Tuesday's session at $6.50 up 1.56 percent. Volume was 21,098.

Medical Connections Holdings, Inc. (MCTH)

Today, Penny Stock Finder, Beacon Equity Research, HotOTC.com, Stock Rich, Cool Penny Stocks, and OTC Picks reported on Medical Connections Holdings, Inc. (MCTH), SmallCap Voice, Stock Stars, Free Investment Report, Pennypic, Titan Stocks, Stock Guru did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTC Bulletin Board, Medical Connections Holdings, Inc. is a national provider of medical recruitment and staffing services. The Company came into being in 2002 to satisfy the increasing need for highly qualified healthcare professionals. Their business is to identify, select, and place the industry’s most talented healthcare specialists, nurses, pharmacists, physicians, and hospital management executives. Headquartered in Boca Raton, Florida, Medical Connections provides recruiting and staffing services for permanent and contract positions, leaving options for both clients and candidates to decide the optimal formula for working together.

Medical Connections corporate commitment is to deliver recruiting and staffing solutions that maximizes the value of the human assets in any healthcare enterprise. They work to deliver fast, cost effective, and high quality services that allow their clients to access and profit from the best medical professionals in the United States and internationally.

The Company works so that searching and retaining the most qualified medical and scientific personnel is not time consuming and costly for their customers. They utilize the extensive expertise of their Recruiters and Pronto Advisers™. They make the searching and retaining process fast, easy, comprehensive, and cost effective for those who use their services. Medical Connections selects, recruits, screens, and places talented medical professionals, domestically and abroad to meet the growing needs facing the health care industry. Medical Connections Holdings, Inc. was named last year to Staffing Industry Analysts' list of fastest-growing U.S. staffing firms for 2009.

Medical Connections has completed the final phases of due diligence of the acquisition of a national healthcare staffing company. Medical Connections is in the final stages of completing this acquisition and hopes to have it completed within the first quarter of 2010. This national company has an operation with virtually the same business lines as Medical Connections Holdings, Inc.

Medical Connections Holdings, Inc. (MCTH) closed today's trading at $0.52 up 20.93 percent. Volume was 780,495.

m-Wise Inc. (MWIS)

Microcap Voice reported earlier on m-Wise Inc. (MWIS) and today we highlight the Company, here at the QualityStocks Daily Newsletter.

m-Wise Inc. is a leading international provider of enabling technologies for the mobile communications, mobile advertising, mobile gaming and mobile entertainment industries. Trading on the OTCBB, the Company is the developer of MOMA platform. This is a mobile content management and service delivery platform used in over 50 mobile networks throughout Europe, North and Latin America, and Asia. Founded in 2000, m-Wise Inc. has their headquarters in New York, New York. The Company also has an Israel office in Hertzelya, Israel and an office in Madrid, Spain.

MOMA is an integrated "one stop shop" for mobile operators, wireless ASPs, and content providers. MOMA makes it easy to manage and deliver content. This includes entertainment, music, games and video regardless of handset compatibility. It does this while adding real-time end user interactivity like voting, mobile marketing, advertising and access to all forms of real-time content. Additionally, to satisfy the growing needs of major brands and marketing agencies, MOMA integrates built-in capabilities for transactional billing, customer care and marketing.

The Company's MOMA Service Delivery Platform includes carrier-grade application provisioning and development utilities, infrastructure connectivity layers, billing, global delivery, content management, and customer support tools. This platform enables fast and efficient development and generation of various value-added services over wireless networks. It also ensures high quality product delivery and minimal time-to-market.

The MOMA Content Management and Delivery Platform (MOMA CDP) connects remotely to the infrastructure of any mobile operator or SMS aggregator. The MOMA CDP installs on redundant, scalable, high availability hardware and software configuration and it hosts at m-Wise's secured datacenter.

m-Wise Inc.'s client list includes Universal Music Group, Arvato Mobile, Thumbplay, Boltcel, and The Secret. Their client list also includes Zero9, SupportComm, The Sun, the Times, Comverse, Pabrune, Interchan, LogiaMobile, and ePLDT.

m-Wise Inc. (MWIS) closed today's trading session at $0.0360 up 24.14 percent. Volume was 239,231.

Flamel Technologies SA (FLML)

Motley Fool Hidden Gems reported earlier on Flamel Technologies SA (FLML), and we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Flamel Technologies, S.A. is a biopharmaceutical company that trades on the NASDAQ Global Market. The Company principally engages in the development of two unique polymer-based delivery technologies for medical applications. Founded in 1990, Flamel Technologies SA turns already-marketed or new drugs into more effective and safer medicines. The Company has assembled a strong team of researchers expert in polymer science and biochemistry; including more than 35 Ph.D.s. Flamel Technologies SA has their corporate headquarters in Venissieux, France.

The Company's Micropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel designed their Medusa® technology to deliver controlled-release formulations of proteins, peptides, and other large and small molecules. They are applying their Medusa platform to improve partners' already-marketed and novel biologics with respect to safety and efficacy, as well as with better pharmacokinetics. Medusa also offers important solutions to threshold issues such as aggregation and solubility.

Two world-renowned scientists help Flamel in their research and development work: Jean-Marie Lehn (Nobel Laureate in Chemistry in 1987) and Professor Christian Trepo, a world-renowned expert in liver diseases. Flamel Technologies owns a 103,900-square foot pharmaceutical production facility in Pessac, France. The facility provides Flamel with the capability to manufacture their "Good Manufacturing Practice" (cGMP)-grade pharmaceutical drugs for clinical trials utilizing their Micropump® or Medusa® technologies.

Flamel Technologies announced in November 2009 that Pfizer exercised their option to license Flamel's Medusa® technology. This technology is for the development of a controlled release formulation of an already-marketed therapeutic protein. Flamel will receive a further payment of $1 million pursuant to the exercise of the license. Pfizer will pay all development costs of the program, including milestone payments and royalties on any commercial sales.

In December 2009, Flamel announced the initiation of a Phase 2a clinical trial of their Interferon alpha-2b XL (IFN-alpha-2b XL). It is based on Flamel's Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is undergoing development as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV). This Phase 2a randomized study, known as ANRS HC 23 COAT-IFN (COnfirmation of Anti-viral activity and Tolerance of Interferon alpha-2b XL), is sponsored by the Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS).

The design of the Phase 2a study is to evaluate IFN-alpha-2b XL in combination with ribavirin in genotype-1 chronic hepatitis C patients who are either naive to treatment or previous non-responders to standard interferon therapy (PEGylated interferon plus ribavirin).

Flamel Technologies SA (FLML) closed Tuesday's trading session at $8.60 for no change. Volume was 29,604.

Fonix Corporation (FNXC)

SmallCap Voice, PennyOmega.com, HotOTC.com, OTC Picks, StockEgg.com, Penny Invest, Stock Rich, and Cool Penny Stocks reported previously on Fonix Corporation (FNXC), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Founded in 1994, Fonix Corporation owns Fonix Speech, Inc., an innovative speech recognition and text-to-speech technology company. The Company provides speech interfaces for devices and systems. Fonix Corporation has their corporate headquarters in Salt Lake City, Utah. They trade on NASDAQ's OTCBB.

Fonix Speech offers speech technology solutions for mobile/wireless devices; interactive electronic games, toys and appliances; computer telephony systems; the assistive market and vehicle telematics. They provide developers and manufacturers with cost-effective speech solutions to enhance consumer devices and systems. Fonix Speech licenses their speech technology to global OEMs and software development companies with established sales channels and dominant market positions.

Fonix Speech customers distribute consumer products in the form of electronic dictionaries, electronic games, mobile phones, PDAs, 511 and telephony systems, toys, GPS and automotive solutions. Fonix Speech receives license fees and unit royalties on the sale of these devices.

Fonix has received various patents which are for certain elements of the Company's core technologies. They have filed applications for other patents covering various aspects of their technologies. The Company looks to develop relationships and strategic alliances with third-party developers and vendors in telecommunications, computers, electronic devices, and related industries. This includes producers of application software, operating systems, computers, and microprocessor chips. They generate revenues through licensing of speech-enabling technologies, maintenance contracts, and services.

For the three months ended September 30, 2009, the Company generated revenues of $335,000. They had net income of $230,000. Third Quarter Company highlights included launching VoiceSync 1.0. This is a Speech Recognition Technology for animation developers. Additionally, almost ten million e-Dictionary and cell phone units sold through Asian OEMs with Fonix embedded software.

In addition, Inventec Besta embedded Fonix Speech Software into the new "Language Learning" electronic dictionary for China, Taiwan, and Korean markets. Fonix VoiceSync 1.0 was licensed for Microsoft's South Park Xbox LIVE Arcade video game, and Autodesk licensed Fonix VoiceIn 4.2 Speech Software.

Fonix Corporation (FNXC) closed Tuesday's trading session at $0.0019 up 18.75 percent. Volume was 25,110,880.

The QualityStocks Company Corner

Cityside Tickets, Inc. (CIST)

The QualityStocks Daily Newsletter would like to spotlight Cityside Tickets, Inc. (CIST). Today, Cityside Tickets, Inc. closed trading at $0.89, which was up 140.54 percent. Their volume today was 211 shares.

Cityside Tickets, Inc. (CIST) offers a diverse range of tickets for sale through their website at www.citysidetickets.com. In addition, visitors to the company’s website can use the site to sell tickets they have available. Cityside Tickets’ focus is on offering tickets to quality theatre acts in a variety of cities.

The company offers concert tickets, theatre tickets, and sports tickets to their customers. Currently, Cityside Tickets is offering concert tickets for acts such as Taylor Swift, Bon Jovi, Lady Gaga, and Elton John & Billy Joel, to name a few. For Theatre tickets, the company is offering tickets for Wicked, The Jersey Boys, South Pacific, and Phantom of the Opera, among others.

Cityside Tickets also offers tickets to Major League Baseball, NBA Basketball, NFL Football, and NHL Hockey events. They also offer Monster Jam tickets, National Finals Rodeo tickets, Ultimate Fighting Championship tickets, U.S. Open Tennis Championship tickets, and WWE-World Wrestling Entertainment tickets.

Additionally, Cityside Tickets offers tickets to NASCAR racing events. This includes tickets to the Daytona 500 at Daytona International Speedway as well as the Atlanta Motor Speedway, Darlington Raceway, Indianapolis Motor Speedway, Michigan International Speedway, Pocono Raceway, and Watkins Glen International. This is in addition to a host of other racetrack offerings presented on the company’s web portal. Disclaimer

Cityside Tickets, Inc. Blog

Cityside Tickets, Inc. News

Jeffrey M. Eckman Resigns From The UpTurn, Inc. and Richard O. Weed is Elected as Sole Officer and Director

National Automation Services, Inc. (NASV) 

The QualityStocks Daily Newsletter would like to spotlight National Automation Services, Inc. (NASV). Today, National Automation Services, Inc. closed trading at $0.07, which was up 14.01 percent. Their volume today was 53,300 shares.  

National Automation Services, Inc. (NASV) is a public holding company focused on designing, engineering, installing and maintaining automated control systems for such business applications as waste water treatment, water treatment, airport security, bottling plants, power plants, metals, mining, breweries, food processing, tire making, textiles, plastics and nearly all production activities.  

Dominant players in the $500 Billion national and international automation controls market include Siemens, Honeywell, Fisher Controls, Johnson Controls and others. In addition to the multi-nationals, it has been estimated that there could be as many as 300 local and regional firms providing automation control services. In general, these companies have an edge on the larger behemoths because they can better respond to the needs of local business and municipalities.  

Unfortunately, for these smaller companies, they compete in a limited market space, have stunted growth prospects and have no way of monetizing their asset value. NAS aims to capitalize on this condition by acquiring and integrating the strongest local and regional players into a new organization that would allow for the synergies and efficiencies of a national company while keeping the competitive advantages of decentralized management and service.  

Of the 300 local and regional automation companies, 42 meet the company’s acquisition criteria; 11 of which have been targeted for acquisition over the next two years. NAS projects year-end 2010 revenues of more than $47 Million and year-end 2011 revenues of over $140 Million predicated on meeting its targeted acquisition schedule. With a solid business plan in place, NAS has a firm foundation to generate strong cash flow and increase shareholder value over the long-term. Disclaimer

National Automotion Services, Inc Blog

National Automation Services, Inc. News:

National Automation Services Announces 3rd Quarter Results and Other NAS Updates

National Automation Services, Inc. $440,000 Awarded Contract for the City of Glendale

National Automation Services, Inc. Fully Reporting Status With SEC

Energtek, Inc. (EGTK)

The QualityStocks Daily Newsletter would like to spotlight Energtek, Inc. (EGTK). Today Energtek, Inc. closed trading at $0.2790, which was up 9.41 percent. Their volume today was 1,000 shares.

Energtek, Inc. (EGTK) is focused on developing and commercializing Adsorbed Natural Gas (ANG) technology. This technology enables the storage of comparable gas quantities at reduced pressure, dramatically decreasing the capital investment and operational costs of natural gas vehicles. The company recognizes the global markets' demands to diversify energy sources and is working on breakthrough technologies that deliver natural gas to the consumer, even where no gas pipeline and compressing infrastructure exist.

Because natural gas is cheaper, cleaner and available in greater quantities than oil, Energtek believes it is the most practical motor fuel alternative. Natural gas is primarily comprised of methane, which is one of the simplest and most abundant substances found in nature, especially when compared to oil. Taking advantage of natural gas resources located across the globe will also reduce the number of countries forced to import motor fuel, including the USA.

The percentage of Natural Gas Vehicles (NGVs) in many countries is growing rapidly. Today, there are more than 8.7 million NGVs on the road, a number that is growing by more than 30% per year. Even with this robust growth, NGVs still represent only a small percentage of the overall vehicle market. Until now, costly refueling infrastructure, as well as the inconvenience of integrating NG tanks into vehicles, has limited the growth of NGVs. However, by enabling the use of natural gas in places previously impossible, Energtek's proprietary ANG technology promises to greatly expand the NGV market.

CEO Lev Zaidenberg leads the company with extensive experience starting and managing several successful hi-tech companies in Israel, Europe and the USA. Mr. Zaidenberg received a B.Sc. in Applied Mathematics and an MBA from Tel-Aviv University. Professor Yuri Ginzburg serves alongside Zaidenberg with a PhD / D.Sc in Mechanical Engineering and a comprehensive background in the automotive industry. Ginzburg is a specialist in alternative fuel systems and R&D projects management, and has authored 18 patents and over 70 scientific works. Disclaimer

Energtek, Inc. Company Blog

Energtek, Inc. News:

Energtek Completes Production of World's First LMP(TM) Low-pressure Semi-Trailer

Energtek Identifies Commercial Consumer for Natural Gas Extracted on Site in Israel

Energtek Anticipates Increase of NatGas Activities in India and FMC Technologies Awarded $30 Million Contract for StatoilHydro's Peregrino Project

Kraig Biocraft Laboratories, Inc. (KBLB)

The QualityStocks Daily Newsletter would like to spotlight Kraig Biocraft Laboratories, Inc. (KBLB) Today, Kraig Biocraft Laboratories, Inc. closed trading at $0.0120, which was up 4.35 percent from yesterday's close. Their volume today was 191,000 shares.

Kraig Biocraft Laboratories, Inc. (KBLB) a biotechnology company, has their focus on developing high performance polymers and technical fibers. The company is utilizing their proprietary genetic engineering technology to develop and produce polymers and protein-based materials, including Spider silk, which may have numerous commercial and consumer applications.

Kraig Biocraft Laboratories, Inc. (KBLB) is working with university scientists and laboratories to create these new polymers that have potentially broad applications in the multi-billion dollar marketplace for high performance polymers. The company sponsors and collaborates on research projects within university genetic engineering laboratories as a means of utilizing the greatest minds in their field.

Spider Silk is one of the strongest fibers produced in nature. The spider's repelling silk is of particular commercial interest since it is both extremely strong and extremely flexible. Although exciting commercial opportunities exist for the natural polymer, there is no known way to produce the fibers in commercial quantity. KraigLabs, in cooperation with two leading universities, has acquired proprietary genetic engineering technology to unlock the mystery.

CEO Kim Thompson leads the company with formal education in the fields of economics and law. With interest in genetic engineering dating back to the 1970s, Mr. Thompson has invented a pending provisional patent application for a number of organic polymers. This patent application has been assigned to benefit Kraig Biocraft and is a central part of the company's efforts in bringing those inventions to the market. Disclaimer

Kraig Biocraft Laboratories, Inc. Blog

News for Kraig Biocraft Laboratories Inc.

The New Age of Partnerships

Kraig Biocraft Laboratories, Inc. Greatly Exceeds Its Performance Goals

SectorWatch.biz: Paving the Way for Spider Silk

National Automation Services, Inc. (NASV) Is In Control

In much of the desert southwest, the name National Automation Services Inc. is rapidly becoming synonymous with control systems integration, though the company has expanded into a number of different areas. The diversity of their projects gives an idea of their ability to solve almost any kind of processing and systems control challenge, but it also indicates the level of trust major clients routinely place in that ability.

• Southwest Airlines – NAS is responsible for maintaining baggage handling for Las Vegas McCarran International Airport, involving extensive use of PLC Controllers, and the integration of numerous monitoring and security systems. NAS has now been asked by Southwest to support all of their operations throughout the western U.S., including California, Arizona, Utah, Oregon, Washington, New Mexico, and Texas.

• Honeywell Security Division – Alaska Pipeline – NAS manufactured four different types of specialty panels used for critical station security on the Alaska pipeline.

• Western Mining & Minerals – NAS supports all automation and controls for their St. George operations, including emergency and scheduled services of PLC, SCADA, and instrumentation at the plant.

• City of Mesa, Arizona – Configuration, programming, and integration for water, wastewater, gas and electric utilities divisions.

• San Carlos Irrigation – Radio Telemetry Survey – NAS designed and implemented a spread spectrum radio network for the San Carlos Irrigation District in Arizona.

• TRW Discrete Parts Manufacturing – NAS developed a semi-automated air bag production line for TRW, involving RF tags and readers, bar code scanners, operator and communications interfaces.

• Watson Pharmaceuticals – NAS was responsible for configuration of Fix 32 SCADA redundancy as well as pure water panel fabrication.
Add to this process control work for companies like Motorola Semiconductor, Coca-Cola Bottling, Chevron, Air Science Engineering, Phelps Dodge, and a wide range of towns and cities in the Southwest, and you get an idea of the company’s flexibility and reputation.

Consorteum Holdings, Inc. (CSRH) Led by an Exceptional Management Team

Consorteum Holdings Inc. is a leader in the payments and transactions industry worldwide. The company has taken special care in assembling a dedicated management and consulting team that has a diverse base of knowledge in the financial services, payment and transaction processing industry. Together the team has accumulated more than a century of high-level expertise.

Director and CEO Craig Fielding has nearly 20 years of global business experience. He previously served in senior management roles in systems, sales and service for Xerox in North America. Mr. Fielding has also successfully developed consulting businesses, sat on the management team at Soft Tracks Enterprises, and was part of the start-up management team at Mint Technology Corp. He brings a wealth of expertise in the payments industry, in both local and international payment processing.

President/COO and director Quent Rickerby brings more than 20 years of business management, international and domestic sales experience, new company start-up and project management experience. In addition, he brings extensive experience in the gift, payroll prepay card, payment and transaction processing, and financial services industries.

Chairman and director James D. Beatty has accumulated 40 years of experience in the investment industry and for the past 30 plus years has focused on the financing and development of small and medium-sized companies. He has sat on more than 30 public company boards in both Canada and the United States, and currently chairs three public company boards.

Vice-president of new business development Jim M. Henry has over 25 years of expertise in business and product development, process management, sales, marketing and directing operations. He also has direct experience in the transaction processing business and operations and card issuing for the financial, retail and telecommunications sectors.

Director of project management Caitlin Snyder brings over 20 years of experience in the prepaid credit card, mobile payment, software development, marketing and new media industries. With over 10 years of start-up experience, she has extensive knowledge and practice in systems integration, national account management, client relations, product development product and program management. Mrs. Snyder recently managed the successful deployment and implementation of over a dozen open loop prepaid card programs including benefits, gift, payroll and retail cards.

All in all, it’s an impressive team… a team whose high level of expertise will be crucial to leading Consorteum Holdings towards a bright and successful future.

GenSpera, Inc. (GNSZ) Receives US Patent for Tumor Activated Prodrugs

Today, GenSpera, Inc. announced that the United States Patent and Trademark Office has issued the company’s patent application, entitled “Tumor Activated Prodrugs,” as US Patent 7,635,682. The patent covers the composition and potential uses of GenSpera’s G-115 second anti-cancer drug, which is currently in development.

GenSpera, Inc. owns and controls all rights to G-115. The company anticipates a strategic partnership to maximize the drug’s value as it progresses through future clinical trials. G-115 can be selectively activated within prostate tumors by an enzyme, Prostate Specific Antigen (PSA), which is active only within prostate tissue and prostate cancer tumors. In preclinical testing, G-115 was shown to dramatically inhibit the growth of tumors in animal models of human prostate cancer.

GenSpera CEO and President, Dr. Craig Dionee, Ph.D., stated, “The company commented that the issuance of this patent further strengthens GenSpera’s intellectual property position for G-115 and its uses for prostate cancer and other prostate pathologies including enlarged prostate.

Dr. Dionne continued, “We are also pleased that the term of this patent will extend into the year 2026, which is a very important feature when we enter discussions with future development partners.”

China Medicine Corp. (CHME) Announces Closing of Financing, New Board Member

China Medicine Corp. is a developer, manufacturer and leading distributor of western pharmaceuticals, traditional Chinese medicines, nutriceuticals and other medical formulations in China. The company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China.

The company announced today that it has closed the equity private placement contemplated in its stock subscription agreement dated December 31, 2009. It completed the placement with One Equity Partners, the global private equity investment arm of JPMorgan (NYSE: JPM). China Medicine sold 4 million of the company’s common shares at $3 per share for $12 million in gross proceeds and 1.92 million of its redeemable convertible preferred shares at $30 per share for $57.6 million in gross proceeds, bringing the total to $57.6 million in gross proceeds resulting in net aggregate net proceeds of $66.5 million. Most of the proceeds have been placed in escrow and will be released to fund future capital expenditures and acquisitions.

China Medicine also announced that Mr. Ryan Shih, resident partner in One Equity Partners’ Hong Kong office, has joined the company’s board of directors. Prior to joining One Equity, he was an investment banker at both Merrill Lynch and Deutsche Bank covering the semiconductor, hardware, media and alternative energy sectors throughout the Asia-Pacific region.

Chairman and CEO of China Medicine, Senshan Yang, spoke of the closing of the transaction, “The closing of this transaction further augments our ability to execute our growth strategy.” With the newly added manufacturing capabilities from the recent LifeTech Pharmaceuticals acquisition, Mr. Yang believes that the company is well on its way “to becoming a vertically integrated pharmaceutical company with self-manufactured products sold through our extensive distribution network.”

 


Sponsors of the Day

 

The QualityStocks Public Company Sponsor News

QualityStocks


 

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336